PP
SGYP

PDT Partners’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

PDT Partners’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-20,600
Closed -$171K – 1718
2015
Q2 		$171K Buy
+20,600
New +$99.8K ﹤0.01% 1258

Other funds holding SGYP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PDT Partners's SGYP Position: Q3 2015 in Review

PDT Partners sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q3 2015, closing a stake of 20,600 shares — an estimated $171K sold.

PDT Partners first reported a position in SGYP in Q2 2015 and held it in 1 quarter. The position peaked at $171K in Q2 2015. 129 funds tracked by Wall St. Rank hold SGYP as of Q3 2015.

  • PDT Partners reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q3 2015 after selling out during the quarter.
  • PDT Partners sold 20,600 Synergy Pharmaceuticals, Inc Common Stock shares in Q3 2015, an estimated $171K.
  • PDT Partners first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2015 and held it in 1 quarter.
  • PDT Partners's Synergy Pharmaceuticals, Inc Common Stock position peaked at $171K in Q2 2015.
  • 129 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q3 2015.

Based on PDT Partners's 13F filing for Q3 2015, filed 16 Nov 2015.